[Comparison study of two glimepiride formulations bioavailability in healthy volunteers of both sexes after a single dose administration].
To compare the bioavailability of two glimepiride 4-mg tablet formulation in 26 healthy volunteers of both sexes. The study was conducted open with randomized two-period crossover design and a 14-day washout period. Samples were obtained over a 48-hour interval. Glimepiride concentrations were analyzed by LC-MS-MS. From the glimepiride plasma concentration versus time curves the following pharmacokinetic parameters were obtained: AUC(0-last), AUC(0-t), AUC(0-infinity), Ke, T1/2, Cmax, and Tmax. Geometric mean of Glimepirida/Amaryl 4 mg was 102.35% for AUC(0-t), 102.35% for AUC(0-infinity) and 99.31% for Cmax. The 90% CI was 92.62-109.55%; 95.62-109.55% e 88.60-111.32%, respectively. Since the 90% CI for both Cmax, AUC(0-t), and AUC(0-infinity) were within the interval of 80-125%, it was concluded that both formulations were bioequivalent, according to both the rate and extent of absorption.